Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Zentalis Pharmaceuticals (ZNTL) has announced the granting of inducement stock options to three newly hired employees on April 1, 2025. The Compensation Committee approved non-qualified stock options to purchase 140,000 shares of common stock under the company's 2022 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $1.39 per share, matching the closing price of Zentalis' stock on The Nasdaq Global Market on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in monthly installments over the following three years, subject to continued employment.
Positive
- Stock-based compensation aligns new employee interests with shareholders
Negative
- Potential shareholder dilution from 140,000 new shares
News Market Reaction – ZNTL
On the day this news was published, ZNTL declined 2.52%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on April 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 140,000 shares of the Company’s common stock to three (3) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
Vesting of the stock options is subject to the employees’ continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
Contacts:
Haibo Wang – Chief Business Officer
Ron Moldaver – Investor Relations
ir@zentalis.com
FAQ
What are the vesting terms for ZNTL's April 2025 inducement stock options?
How many shares were granted in Zentalis' April 2025 inducement stock options?
What is the exercise price for ZNTL's April 2025 inducement grants?
How long is the term of ZNTL's April 2025 inducement stock options?
